Written answers
Tuesday, 28 November 2023
Department of Health
Disease Management
Richard Bruton (Dublin Bay North, Fine Gael)
Link to this: Individually | In context | Oireachtas source
589. To ask the Minister for Health if he has evaluated the dexcom diabetes treatment pillars, which have been submitted for consideration by the Houses of the Oireachtas; and if he is in a position to put them into action. [52073/23]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
The Health Service Executive (HSE) has statutory responsibility for decisions on pricing and reimbursement under the community schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. In making a relevant reimbursement decision, the HSE is required under the Act to have regard to a number of criteria including clinical efficacy, the health needs of the public, cost effectiveness and potential or actual budget impact.
Both the Dexcom G6 and Dexcom G7 are currently available to eligible persons for the purpose of glucose monitoring.
The Health Information and Quality Authority completed a Health Technology Assessment (HTA) in respect of the provision of glucose monitoring systems to adults with Type I diabetes in Ireland. This was published on 29 September 2023.
The HSE has accepted the recommendations made in the HTA and is currently designing a single managed access programme for glucose monitoring systems with clearly defined eligibility criteria.
No comments